Drug Combination Details
| General Information of the Combination (ID: C55696) | |||||
|---|---|---|---|---|---|
| Name | Celastrol NP Info | + | Bortezomib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CXCR4 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | ||
| NCI-H929 | CVCL_1600 | Plasma cell myeloma | Homo sapiens | |||
| KMS-11 | CVCL_2989 | Plasma cell myeloma | Homo sapiens | |||
| In-vivo Model | Male athymic balb/c nude mice were implanted with 2 * 106 cells with Human MM U266 cell lines subcutaneously. | |||||
| Experimental
Result(s) |
Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma. | |||||
